EDDING GENOR (06998): Completion of drug administration for the first subject in the Phase II clinical trial of GB268.

EDDING GENOR (06998) announced that the first patient administration in the Phase Ib/II clinical trial of its highly differentiated and innovative PD-1/CTLA-4/VEGF tri-specific antibody GB268 for the treatment of locally advanced unresectable or metastatic breast cancer (including triple-negative breast cancer TNBC and hormone receptor-positive/HER2-negative HR+/HER2- breast cancer) was successfully completed on August 5, 2026. The study includes monotherapy, immune combination chemotherapy, and immune combination antibody-drug conjugate regimens. The primary endpoints are to evaluate the safety and tolerability of GB268 in combination, including dose-limiting toxicity (DLT), as well as to assess the preliminary anti-tumor activity of GB268 as monotherapy and in combination with different treatment regimens in the corresponding breast cancer populations. This clinical program spans first-line and later-line comprehensive treatment phases, marking the first step towards broadly expanding the application scope of GB268. In the future, the company also plans to carry out multiple combination therapy clinical studies in more advanced solid tumor fields. The Phase I clinical data for GB268 as a monotherapy is scheduled to be presented at the European Society for Medical Oncology (ESMO) in the fourth quarter of 2026.